EUCTR2013-001436-22-GB进行中（未招募）1 期
Does ALlopurinol regress lefT ventricular hypertrophy in End stage REnal Disease: The ALTERED study - The Altered Study
niversity of Dundee/NHS Tayside0 个研究点目标入组 86 人开始时间: 2013年6月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 86
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •are aged 18 to 80 years
- •end stage renal disease (CKD stage 5 eGFR <15ml/min /1.73m2)
- •been on haemodialysis for at least 3 months.
- •For main study also require echocardiographic LVH according to the ASE (American Society of Echocardiography) criteria of LVM =115g/m2 for men and >95g/m2 for women.
- •All concomitant medication will be allowed and continued unchanged unless clinically indicated during the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 26
排除标准
- •Known heart failure
- •Left Ventricular Ejection Fraction <45%,
- •already had gout or on allopurinol,
- •severe hepatic disease
- •or on azathioprine, 6 mercaptopurine, theophylline or warfarin.
- •malignancy or other life threatening diseases,
- •pregnant or lactating women
- •any contraindication to MRI (claustrophobia, metal implants).
- •with a planned (relative) kidney transplant,
- •Aged less than 18 or over 80 years
- •Above ankle amputees
- •Patients who have participated in any other clinical trial within the previous 30 days will be excluded.
- •Patients who are unable to give informed consent will also be excluded from this trial.
研究者
相似试验
进行中（未招募）
1 期
The ALLAY trialeft ventricular hypertrophy in hypertensionMedDRA version: 17.0 Level: PT Classification code 10049773 Term: Left ventricular hypertrophy System Organ Class: 10007541 - Cardiac disordersMedDRA version: 17.0 Level: PT Classification code 10015488 Term: Essential hypertension System Organ Class: 10047065 - Vascular disordersEUCTR2014-002083-33-GBniversity of Dundee/NHS Tayside66
已完成
不适用
Does allopurinol reduce thickening of the left ventricle of the heart in patients with treated hypertension?Essential hypertensives with left ventricular hypertrophyCirculatory SystemISRCTN40476871The University of Dundee and NHS Tayside (UK)72
已完成
4 期
Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension?Hypertrophy, Left VentricularHypertensionNCT02237339University of Dundee72
已完成
不适用
Does allopurinol prevent adverse left ventricular remodelling post-myocardial infarction?Myocardial infarctionCirculatory SystemISRCTN57354520niversity of Dundee (UK)36
进行中（未招募）
1 期
The ALPHA Trialright ventricular hypertrophy associated with COPD or Interstitial Lung Disease and pulmonary hypertensionMedDRA version: 17.1 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 17.1 Level: PT Classification code 10022611 Term: Interstitial lung disease System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 17.1 Level: PT Classification code 10037400 Term: Pulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 17.1 Level: PT Classification code 10050326 Term: Right ventricular hypertrophy System Organ Class: 10007541 - Cardiac disordersEUCTR2014-002305-38-GBniversity of Dundee/ NHS Tayside72